Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases
Authors:
Open Access
- 21 May 2022
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (8) , 1825-1834
Abstract
COVID-19 in patients with hematological diseases is associated with a high mortality. Moreover, preventive vaccination demonstrated reduced efficacy and the knowledge on influencing factors is limited. In this single-center study, antibody levels of the SARS-CoV-2 spike protein were measured ≥ 2 weeks after 2nd COVID-19 vaccination with a concentration ≥ 0.8 U/mL considered positive. Between July and October 2021, in a total of 373 patients (median age 64 years, 44% women) with myeloid neoplasms (n = 214, 57%), lymphoid neoplasms (n = 124, n = 33%), and other diseases (n = 35, 10%), vaccination was performed with BNT162b2 (BioNTech), mRNA-1273 (Moderna), ChADOx1 (AstraZeneca), or a combination. A total of 229 patients (61%) were on active therapy within 3 months prior vaccination and 144 patients (39%) were previously treated or treatment naïve. Vaccination-related antibody response was negative in 56/373 patients (15%): in 39/124 patients with lymphoid neoplasms, 13/214 with myeloid neoplasms, and 4/35 with other diseases. Active treatment per se was not correlated with negative response. However, rituximab and BTK inhibitor treatment were correlated significantly with a negative vaccination response, whereas younger age and chronic myeloid leukemia (CML) disease were associated with positive response. In addition, 5 of 6 patients with myeloproliferative neoplasm (MPN) and negative vaccination response were on active treatment with ruxolitinib. In conclusion, a remarkable percentage of patients with hematological diseases had no response after 2nd COVID-19 vaccination. Multivariable analysis revealed important factors associated with response to vaccination. The results may serve as a guide for better protection and surveillance in this vulnerable patient cohort.Keywords
Funding Information
- Medizinische Fakultät Heidelberg der Universität Heidelberg
This publication has 30 references indexed in Scilit:
- Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant DiseaseJAMA Oncology, 2021
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for CancerJAMA Oncology, 2021
- Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum SamplesJAMA, 2021
- In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic PatientsInfectious Diseases and Therapy, 2021
- COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registryAnnals of Hematology, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLeukemia, 2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19British Journal of Haematology, 2020
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialThe Lancet Oncology, 2018